Target intelligence / Profile preview

X-prolyl aminopeptidase 1 (XPNPEP1)

Target
XPNPEP1
Molecular classification
Enzyme, Metallopeptidase (specifically, proline-specific metalloaminopeptidase)
01

Overview

X-prolyl aminopeptidase 1 (XPNPEP1) is a cytosolic metalloaminopeptidase that catalyzes the cleavage of N-terminal amino acids from peptides where the second residue is proline, a bond that most peptidases cannot hydrolyze[1][3][5]. It is essential for the maturation and breakdown of various bioactive peptides, including peptide hormones, neuropeptides, tachykinins, and fragments of dietary proteins[3][5]. The enzyme operates as a manganese-dependent homodimer in humans, features a unique three-domain structure, and has been implicated in cardiovascular pathophysiology through its role in bradykinin inactivation, as well as in some renal and metabolic disorders when deficient[1][5]. Experimental inhibitors like apstatin bind to the metal center and block substrate processing, providing a tool for mechanistic study[2]. The gene encoding XPNPEP1 is located on chromosome 10q25.1 and produces multiple splicing variants[5]. Proteome and structural analyses show that the enzyme shares conserved mechanisms and substrate specificity with other X-prolyl peptidases[1][2].

Other names
Xaa-Pro aminopeptidase 1Aminoacylproline aminopeptidaseSoluble aminopeptidase PAPP1SAMPXPNPEPXPNPEPLXPNPEPL1Cytosolic aminopeptidase PX-prolyl aminopeptidase (aminopeptidase P) 1, soluble
02

Mechanism of action

Inhibition of X-prolyl aminopeptidase 1 blocks the removal of N-terminal amino acids from peptides that have a penultimate proline, which can impact the catabolism of biologically active peptides such as bradykinin[1][2][5].

03

Biological functions

Protein and peptide degradation (removes N-terminal amino acids when next to proline)Maturation and degradation of peptide hormonesDegradation of neuropeptides and tachykininsDigestion of resistant dietary protein fragments
04

Disease associations

Cardiovascular disease (linked to degradation of bradykinin, blood pressure regulation, and myocardial infarction risk)Nephronophthisis 11Potential involvement in peptide hormone-related disorders
05

Safety considerations

Accumulation of proline-containing peptides may have unknown metabolic or physiological effectsInhibition can potentially impact blood pressure regulation, neuropeptide balance, or hormone catabolism[1][5]
06

Interacting drugs

Apstatin (inhibitor used as an experimental probe of enzyme activity)
07

Biomarkers

Elevated urinary imino-oligopeptides in cases of deficiency

Beyond the preview

Go deeper on X-prolyl aminopeptidase 1 (XPNPEP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on X-prolyl aminopeptidase 1 (XPNPEP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call